Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ascendis Pharma A/S (ASND) vs Williams-Sonoma, Inc. (WSM) Price & Performance

Ascendis Pharma A/STrade
Williams-Sonoma, Inc.Trade

Price performance (Past 24H)

Key statistics

Ascendis Pharma A/S vs Williams-Sonoma, Inc. — how do they compare? Ascendis Pharma A/S trades at $256 (market cap $16.67B), while Williams-Sonoma, Inc. trades at $246.37 (market cap $29.51B). The key difference: Williams-Sonoma, Inc. is the larger of the two by market cap, and Williams-Sonoma, Inc. pays a 1.21% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.

ASNDWSM
Market Cap
$16.67B$29.51B
Sector
HealthConsumer Cyclical
52-Week High
$277.18$251.81
52-Week Low
$189.74$168.64
Enterprise Value
$17.04B$30.35B
Dividend Yield
1.21%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ascendis Pharma A/S

Ascendis Pharma (ASND) trades at $255.17, down slightly by 0.18% on the day, while maintaining strong analyst support with 92% buy ratings and a $309.75 consensus price target. The company shows impressive revenue growth from $51M in 2022 to $720M in 2025, with profitability improving as net loss narrows to -$228M. Recent technical indicators show a bullish trend with the stock trading near resistance at $255-257, while fundamental metrics reveal high valuation ratios (P/E 29.05, P/S 15.68) offset by exceptional gross margins of 89.04%.

ASND presents a compelling growth story with multiple product launches in rare endocrine diseases driving revenue expansion, though investors face risks from negative shareholder equity and high debt levels. The company's transition to positive operating cash flow ($54M in 2025) and inclusion in Russell indexes signal maturation, but execution risks remain as the stock trades at premium valuations requiring continued strong performance to justify current levels.

Williams-Sonoma, Inc.

Williams-Sonoma (WSM) trades at $246.14, down 1.87% on the day, amid a generally bullish technical outlook. The stock shows strong profitability with a net income margin of 13.81% and has beaten earnings estimates for three consecutive quarters. Recent news highlights its digital-first transformation and competitive strength in home furnishings.

The outlook is supported by solid fundamentals and positive earnings momentum, but high valuation ratios and overbought RSI levels pose near-term risks. Analyst consensus is mixed, with a moderate buy rating but a price target below the current price, suggesting cautious optimism amid execution and consumer spending concerns.

Returns comparison

Trailing returns across standard periods

About Ascendis Pharma A/S

Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.

Read more on ASND

About Williams-Sonoma, Inc.

With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.

Read more on WSM